VISTABEL

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Ireland, Lithuania, Malta, Poland, Romania, Spain.

Active ingredients

The drug VISTABEL contains one active pharmaceutical ingredient (API):

1	Botulinum toxin type A UNII E211KPY694 - BOTULINUM TOXIN TYPE A
	Botulinum toxin type A is a protein complex derived from Clostridium botulinum. The protein consists of type A neurotoxin and several other proteins. Under physiological conditions it is presumed that the complex dissociates and releases the pure neurotoxin. Intramuscular injection of the neurotoxin complex blocks cholinergic transport at the neuromuscular junction by preventing the release of acetylcholine. The nerve endings of the neuromuscular junction no longer respond to nerve impulses and secretion of the chemotransmitter is prevented (chemical denervation).
	Read more about Botulinum toxin type A

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M03AX01	Botulinum toxin	M Musculo-skeletal system → M03 Muscle relaxants → M03A Muscle relaxants, peripherally acting agents → M03AX Other muscle relaxants, peripherally acting agents
Discover more medicines within M03AX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1161605, 1616015, 1783177, 1783188
ES	Centro de información online de medicamentos de la AEMPS	65837
FI	Lääkealan turvallisuus- ja kehittämiskeskus	022250
FR	Base de données publique des médicaments	68150775
HR	Agencija za lijekove i medicinske proizvode	HR-H-430530691
LT	Valstybinė vaistų kontrolės tarnyba	1017350, 1021234, 1086419, 1086420, 1089500, 1093214
MT	Medicines Authority	MA1304/00301
PL	Rejestru Produktów Leczniczych	100191959
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69201001, W69201002, W69201003, W69201004